Ruta Petraitiene1, Vidmantas Petraitis1, William W Hope2, Thomas J Walsh3. 1. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical Center of Cornell University, New York, New York. 2. Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom. 3. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical Center of Cornell University, New York, New York Department of Pediatrics and Department of Microbiology and Immunology, Weill Cornell Medical Center of Cornell University, New York, New York.
Abstract
BACKGROUND: The current standard of treatment of invasive candidiasis with echinocandins requires once-daily therapy. To improve quality of life, reduce costs, and improve outcome, we studied the pharmacokinetics (PK), efficacy, and safety of alternate dosing regimens of micafungin (MFG) for the treatment of experimental subacute disseminated candidiasis. METHODS: MFG was administered for 12 days starting 24 hours after intravenous inoculation of 1 × 10(3) Candida albicans blastoconidia. Study groups consisted of MFG at 1 mg/kg every 24 hours (MFG1), 2 mg/kg every 48 hours (MFG2), and 3 mg/kg every 72 hours (MFG3), and untreated controls. PK of MFG were determined on day 7 by high-performance liquid chromatography and modeled using nonparametric adaptive grid program. A 2-compartment PK model with volume of the central compartment (Vc), clearance (SCL), and the intercompartmental rate constants Kcp and Kpc was used. The fungal burden in 7 tissues was determined 312 hours after the initiation of therapy. RESULTS: PK of MFG were linear and the parameter means ± SD were Vc = 0.41 ± 0.18 L, Kcp = 2.80 ± 1.55/hour, Kpc = 1.71 ± 0.93/hour, and SCL = 0.16 ± 0.003 L/hour (r(2) = 0.99). The area under the plasma drug concentration - time curve for MFG1, MFG2, and MFG3 was 198.7 ± 19.8, 166.3 ± 36.7, and 192.8 ± 46.2 mg × hour/L, respectively (P = .24). All treatment groups showed significant and comparable resolution of (1→3)-β-D-glucan levels and clearance of C. albicans from liver, spleen, kidney, brain, lung, vitreous humor, and vena cava in comparison to untreated controls (P ≤ .05). There were no differences in hepatic or renal function among study groups. CONCLUSIONS: Less fractionated MFG regimens of every 48 and 72 hours are safe and as effective in experimental disseminated candidiasis as once-daily therapy in neutropenic hosts.
BACKGROUND: The current standard of treatment of invasive candidiasis with echinocandins requires once-daily therapy. To improve quality of life, reduce costs, and improve outcome, we studied the pharmacokinetics (PK), efficacy, and safety of alternate dosing regimens of micafungin (MFG) for the treatment of experimental subacute disseminated candidiasis. METHODS:MFG was administered for 12 days starting 24 hours after intravenous inoculation of 1 × 10(3) Candida albicans blastoconidia. Study groups consisted of MFG at 1 mg/kg every 24 hours (MFG1), 2 mg/kg every 48 hours (MFG2), and 3 mg/kg every 72 hours (MFG3), and untreated controls. PK of MFG were determined on day 7 by high-performance liquid chromatography and modeled using nonparametric adaptive grid program. A 2-compartment PK model with volume of the central compartment (Vc), clearance (SCL), and the intercompartmental rate constants Kcp and Kpc was used. The fungal burden in 7 tissues was determined 312 hours after the initiation of therapy. RESULTS: PK of MFG were linear and the parameter means ± SD were Vc = 0.41 ± 0.18 L, Kcp = 2.80 ± 1.55/hour, Kpc = 1.71 ± 0.93/hour, and SCL = 0.16 ± 0.003 L/hour (r(2) = 0.99). The area under the plasma drug concentration - time curve for MFG1, MFG2, and MFG3 was 198.7 ± 19.8, 166.3 ± 36.7, and 192.8 ± 46.2 mg × hour/L, respectively (P = .24). All treatment groups showed significant and comparable resolution of (1→3)-β-D-glucan levels and clearance of C. albicans from liver, spleen, kidney, brain, lung, vitreous humor, and vena cava in comparison to untreated controls (P ≤ .05). There were no differences in hepatic or renal function among study groups. CONCLUSIONS: Less fractionated MFG regimens of every 48 and 72 hours are safe and as effective in experimental disseminated candidiasis as once-daily therapy in neutropenic hosts.
Authors: Daniel K Benjamin; Timothy Driscoll; Nita L Seibel; Corina E Gonzalez; Maureen M Roden; Rahki Kilaru; Kay Clark; James A Dowell; Jennifer Schranz; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: Thomas J Walsh; Peter C Adamson; Nita L Seibel; Patricia M Flynn; Michael N Neely; Cindy Schwartz; Aziza Shad; Sheldon L Kaplan; Maureen M Roden; Julie A Stone; Alisha Miller; Susan K Bradshaw; Susan X Li; Carole A Sable; Nicholas A Kartsonis Journal: Antimicrob Agents Chemother Date: 2005-11 Impact factor: 5.191
Authors: Nita L Seibel; Cindy Schwartz; Antonio Arrieta; Patricia Flynn; Aziza Shad; Edith Albano; James Keirns; Wendi M Lau; David P Facklam; Donald N Buell; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: M N Gamaletsou; T J Walsh; T Zaoutis; M Pagoni; M Kotsopoulou; M Voulgarelis; P Panayiotidis; T Vassilakopoulos; M K Angelopoulou; M Marangos; A Spyridonidis; D Kofteridis; A Pouli; D Sotiropoulos; P Matsouka; A Argyropoulou; S Perloretzou; K Leckerman; A Manaka; P Oikonomopoulos; G Daikos; G Petrikkos; N V Sipsas Journal: Clin Microbiol Infect Date: 2013-07-24 Impact factor: 8.067
Authors: John D Cleary; Michael Schwartz; P David Rogers; Jacqueline de Mestral; Stanley W Chapman Journal: Pharmacotherapy Date: 2003-08 Impact factor: 4.705
Authors: J L Livermore; T W Felton; J Abbott; A Sharp; J Goodwin; L Gregson; P A Warn; S J Howard; W W Hope Journal: Antimicrob Agents Chemother Date: 2012-10-31 Impact factor: 5.191
Authors: Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll Journal: Clin Microbiol Rev Date: 2019-05-15 Impact factor: 26.132
Authors: George R Thompson; Alex Soriano; Athanasios Skoutelis; Jose A Vazquez; Patrick M Honore; Juan P Horcajada; Herbert Spapen; Matteo Bassetti; Luis Ostrosky-Zeichner; Anita F Das; Rolando M Viani; Taylor Sandison; Peter G Pappas Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079